Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Letter to company
Asset disposition
Appointed director
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/15/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results"
11/10/2021 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results"
08/11/2021 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results"
05/11/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results"
08/13/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results"
08/08/2019 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results"
03/07/2019 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results"
11/07/2018 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results"
08/09/2018 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results"
05/08/2018 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results"
03/08/2018 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results"
08/08/2017 8-K Quarterly results
Docs: "Forward Looking Statements"
05/09/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/17/2016 8-K Form 8-K - Current report
03/29/2016 8-K Quarterly results, Resignation/termination of a director
Docs: "Director Agreement between the Company and Mark I. Greene",
"Director Agreement between the Company and Anthony Fiorino",
"Navidea Announces Fourth Quarter and Full Year 2015 Results"
11/06/2015 8-K Quarterly results
Docs: "Financial tables to follow"
08/05/2015 8-K Quarterly results
Docs: "About Lymphoseek"
05/21/2015 8-K/A Quarterly results
Docs: "Term Loan Agreement, by and among Navidea Biopharmaceuticals, Inc., as borrower, Macrophage Therapeutics, Inc. as guarantor, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P., as lenders (filed herewith)"
05/15/2015 8-K Quarterly results
Docs: "Security Agreement, among Navidea Biopharmaceuticals, Inc. , as borrower, Macrophage Therapeutics, Inc. as guarantor, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P., as lenders, and Capital Royalty Partners II L.P., as control agent",
"Subordination Agreement, among Platinum-Montaur Life Sciences, LLC, as subordinated creditor, Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P., as senior creditors, and Capital Royalty Partners II L.P., as senior creditor agent, and consented to by Navidea Biopharmaceuticals, Inc. as borrower",
"Third Amendment to Loan Agreement, by and between Navidea Biopharmaceuticals, Inc, as borrower, and Platinum-Montaur Life Sciences, LLC, as lender",
"Third Amended and Restated Promissory Note, made by Navidea Biopharmaceuticals, Inc. in favor of Platinum-Montaur Life Sciences LLC",
"Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance DUBLIN OHIO, May 12, 2015 - Navidea Biopharmaceuticals, Inc. , today announced financial results for the first quarter of 2015. Navidea reported total revenue for the first quarter of 2015 of $2.1 million, including Lymphoseek injection sales revenue of $1.84 million. The net loss attributable to common stockholders was $7.3 million. “Performance year-to-date reflects our aggressive transformation into an organization singularly focused on unlocking the value of our Manocept™ technology as a state-of-the-art cancer imaging agent and as a novel therapeutic platform,” said Rick Gonzalez, Navidea Chief Executive Officer. “We executed on our stated objectives to grow revenues sequentially, ...",
"Navidea Secures $60 Million Loan with CRG; Funding to Support Lymphoseek Commercialization and Advancement of Development Pipeline"
03/06/2015 8-K Quarterly results
Docs: "Navidea Announces Fourth Quarter and Full Year 2014 Results"
11/06/2014 8-K Quarterly results
Docs: "Navidea Announces Third Quarter 2014 Financial Results"
08/11/2014 8-K Quarterly results
Docs: "Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million DUBLIN, OHIO – August 6, 2014 -- Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced financial results and business highlights for the second quarter and first half of 2014. Revenue to Navidea from sales of Lymphoseek Injection grew to more than $1 million in the second quarter of 2014, an increase of 67% compared to the first quarter 2014 and an increase of over 700% compared to the second quarter of 2013 when the product was first launched. Based on the sales trends observed, Navidea reiterates its full-year 2014 Lymphoseek revenue expectation of $5 to $6 million. "Lymphoseek sales growth is being driven by favorable..."
05/07/2014 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Announces First Quarter 2014 Financial Results DUBLIN, OHIO -- May 7, 2014 -- Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced its financial results and business highlights for the first quarter of 2014. "As we begin 2014, we are encouraged by the continued advances in utilization, market penetration and account growth for Lymphoseek®. We are realizing increasing traction in our commercial and medical education activities directed toward surgical oncologists and major lymphatic mapping centers,” said Dr. Mark Pykett, Navidea Chief Executive Officer. “We continue to focus our efforts on expanding market opportunities in the U.S. and abroad by obtaining additional regulatory clearan..."
03/07/2014 8-K Quarterly results
Docs: "Loan and Security Agreement, among Oxford Finance LLC, as collateral agent, the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time including Oxford in its capacity as a Lender, and Navidea Biopharmaceuticals, Inc",
"Subordination Agreement, by and among Platinum-Montaur Life Sciences LLC and Oxford Finance LLC, and consented to and acknowledged by Navidea Biopharmaceuticals, Inc",
"Second Amendment to Loan Agreement, between Navidea Biopharmaceuticals, Inc. and Platinum-Montaur Life Sciences LLC",
"Second Amended and Restated Promissory Note, made by Navidea Biopharmaceuticals, Inc. in favor of Platinum-Montaur Life Sciences LLC",
"Form of Series KK Warrants to purchase common stock of Navidea Biopharmaceuticals, Inc. issued to Oxford Finance LLC on March 4, 2014",
"Navidea Announces Fourth Quarter and Full Year 2013 Results",
"Navidea Announces Acceptance for Review of an Additional sNDA to Further Expand Lymphoseek Labeling",
"Navidea Biopharmaceuticals Closes $30 Million Loan with Oxford Finance, LLC"
11/06/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy